Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00343811 · ClinicalTrials.gov registry record · Phase 3
Study to Evaluate the Efficacy of Modafinil Treatment in Patients With Attention Deficit Hyperactivity Disorder (ADHD) Who Are Responders to Modafinil Treatment
A Phase 3 study of Attention Deficit Hyperactivity Disorder, sponsored by Cephalon.
- Completed
- Registry status
- Phase 3
- Development phase
- 120
- Enrollment target
- 20
- Study locations
NCT00343811: Completed Phase 3 study of Attention Deficit Hyperactivity Disorder, sponsored by Cephalon.
NCT00343811 is a Phase 3 study of Attention Deficit Hyperactivity Disorder that has completed, run by Cephalon. The registered enrollment target is 120 participants, below the 215-participant average among 102 other Attention Deficit Hyperactivity Disorder trials with a reported enrollment target (44% lower). The trial reports 20 study locations across 13 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00343811, a Phase 3 study of Attention Deficit Hyperactivity Disorder, has completed, sponsored by Cephalon.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 120 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to evaluate the continued efficacy of modafinil treatment, compared to placebo treatment, in children and adolescents with attention-deficit/hyperactivity disorder (ADHD) who are responders to modafinil treatment.
Conditions Studied
Interventions
- DRUG Modafinil
Study Locations (20)
California
- UCI Child Development Center - Irvine
- University of California at San Francisco - San Francisco
- Encompass Clinical Research - Spring Valley
Florida
- Sarkis Family Psychiatry - Gainesville
- Amedica Research Institute, Inc. - Hialeah
- Miami Research Associates - Miami
Kentucky
- Kentucky Pediatric/Adult Research - Bardstown
- Michael J. Rieser, MD, PSC - Lexington
- Four Rivers Clinical Research, Inc. - Paducah
North Carolina
- Piedmont Neuropsychiatry - Charlotte
- Triangle Neuropsychiatry - Durham
Arkansas
- Clinical Study Centers, LLC - Little Rock
Colorado
- Alpine Clinical Research - Boulder
Georgia
- Child Neurology Associates - Atlanta
Michigan
- Clinical Neurophysiology Services - Troy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 120 participants |
| Start Date | 2006-06 |
| Est. Completion | 2006-09 |
| Phase | Phase 3 |
What the finished NCT00343811 record still lists
NCT00343811 is an interventional study that assigns participants to a tested intervention. The registered 120 participants enrollment target is mid-sized for trials with a published cap, below the 215-participant average among 102 other Attention Deficit Hyperactivity Disorder trials with a reported enrollment target (44% lower).
The record links to 1 condition, with Attention Deficit Hyperactivity Disorder appearing as the primary indexed condition, and to 1 intervention - of which Modafinil is the first listed.
NCT00343811 names 20 study sites across 13 states, led by California, Florida, Kentucky.
Frequently Asked Questions
What is clinical trial NCT00343811 about?
NCT00343811 is a clinical study titled "Study to Evaluate the Efficacy of Modafinil Treatment in Patients With Attention Deficit Hyperactivity Disorder (ADHD) Who Are Responders to Modafinil Treatment". The purpose of this study is to evaluate the continued efficacy of modafinil treatment, compared to placebo treatment, in children and adolescents with attention-deficit/hyperactivity disorder (ADHD) who are responders to modafinil treatment.
What is the current status of trial NCT00343811?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 120 participants. The study started on 2006-06. Estimated completion is 2006-09.
What conditions does trial NCT00343811 study?
This clinical trial studies the following conditions: Attention Deficit Hyperactivity Disorder.
What interventions are being tested in trial NCT00343811?
The interventions under investigation include: Modafinil (DRUG).
Who is sponsoring clinical trial NCT00343811?
This trial is sponsored by Cephalon, which has 64 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00343811 being conducted?
This trial has 20 study locations across Arkansas, California, Colorado, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Attention Deficit Hyperactivity Disorder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00343811's enrollment target sits among peer trials
120 41st of 102 higher than 62 of 102 other Attention Deficit Hyperactivity Disorder trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Attention Deficit Hyperactivity Disorder trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Trial of Centanafadine Long-term Safety in Children and Adolescents With Attention-deficit/Hyperactivity Disorder.
ACTIVE NOT RECRUITING · Phase 3
-
Open-label Study to Evaluate Long-term Safety and Efficacy of SPN-812 (Viloxazine Extended-release Capsule)
ACTIVE NOT RECRUITING · Phase 3
-
Study to Assess the Safety and Efficacy of NRP104 in Adults With Attention-Deficit Hyperactivity Disorder (ADHD)
COMPLETED · Phase 3
-
A Pivotal Efficacy Trial to Evaluate HLD200 in Children With ADHD in a Classroom Setting
COMPLETED · Phase 3
-
Adult Attention Deficit Hyperactivity Disorder (ADHD) Study With Amphetamine Sulfate
COMPLETED · Phase 3
-
Long Term Safety Study of Study Drug (Eszopiclone) in Children and Adolescents With ADHD -Associated Insomnia
COMPLETED · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01174108 · 120 participants · Phase 2
Allogeneic Hematopoietic Stem Cell Transplantation for Severe Aplastic Anemia and Other Bone Marrow Failure Syndromes Using G-CSF Mobilized CD34+ Selected Hematopoietic Precursor Cells Co-Infused With a Reduced Dose of Non-Mobilized Donor T-cells
- NCT01627301 · 120 participants · NA
Sympathetic Overactivity in Post-traumatic Stress Disorder
- NCT02025023 · 120 participants · Phase 3
Local 5-Fluorouracil Injection for the Treatment of Chalazia: A Prospective, Comparative Study
- NCT02128906 · 120 participants · Phase 2
Radiotherapy With Cisplatin vs. Docetaxel-cetuximab in HNSCC: ERCC1 Biomarker Enrichment and Interaction Design
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia